Sat, Aug 30, 2014, 5:05 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Northwest Biotherapeutics, Inc. Message Board

csr1223 15 posts  |  Last Activity: Aug 27, 2014 4:13 PM Member since: Feb 23, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    people must be nuts

    by azrastulic Aug 27, 2014 3:52 PM
    csr1223 csr1223 Aug 27, 2014 4:13 PM Flag

    Look at SRPT, RS followed by TLD on their drug for muscular dystrophy worked out very very well. Suggest you buy any dips following the RS.

    Sentiment: Strong Buy

  • Reply to

    1 for 100 reverse split effective tomorrow

    by csr1223 Aug 27, 2014 2:16 PM
    csr1223 csr1223 Aug 27, 2014 3:52 PM Flag

    In the imortal words of Steve Martin:

    "Well EXCUUSE Meeeeeee".

    I just thought you might like to know.

    CSR

    Sentiment: Strong Buy

  • Reply to

    1 for 100 reverse split effective tomorrow

    by csr1223 Aug 27, 2014 2:16 PM
    csr1223 csr1223 Aug 27, 2014 2:19 PM Flag

    according to multiple posts on twitter $ACTC

  • ACTC will trade as ACTCD following the 1 for 100 reverse split effective tomorrow. I expect the reverse split to be followed shortly by TLD from the AMD trial.

  • csr1223 csr1223 Aug 13, 2014 12:24 PM Flag

    Techtrader,

    I agree that BCLI doesn't look to be in the same class as Neuralstem, however, they do have some quality sites participating in their phase II trial. On July 15, 2014, Brainstorm announced that the University of Massachusetts Memorial Medical Center began enrolling patients in the randomized, double-blind, placebo-controlled Phase 2 clinical trial (NCT02017912) in Amyotrophic Lateral Sclerosis (ALS). This is the second site to open for the trial behind Massachusetts General Hospital, which began enrolling patients in June 2014. The Mayo Clinic, the third site participating in the trial, is expected to become active in the third quarter of 2014.

    csr

    Sentiment: Strong Buy

  • Reply to

    Higher Mammals

    by fasttimesgrad Aug 1, 2014 7:38 PM
    csr1223 csr1223 Aug 6, 2014 10:50 AM Flag

    Now that the last patient has been operated on in the ALS trial, I would imagine that Dr. Boulis will be getting ready to assist in the first surgery in the spinal cord injury trial. I always suspected that the spinal cord injury trial wouldn't begin surgeries until the ALS phase II trial surgeries were completed. Neuralstem has a lot on their plate for such a small company. I, for one, am happy that they are making sure they take care to finish off the phase II ALS trial before they start up the spinal cord injury trial. That said, I think it could get very interesting after the first patient is treated in the spinal cord injury trial at UCSD. People can debate the results of the ALS trial even in the face of unprecedented results from the likes of Ted Harada, however, nobody will be debating the results from the spinal cord injury trial if patients start to regain meaningful use of their legs. Game over if patient(s) respond in this trial. Game, Set and Match, IMHO this could happen before the end of the year.

    csr

    Sentiment: Strong Buy

  • Reply to

    From the 1991 MOU -- maybe editroid can update;;

    by hjsdmi Aug 3, 2014 2:52 PM
    csr1223 csr1223 Aug 4, 2014 10:04 AM Flag

    Any idea when the patent(s) being litigated expire?

    Thanks,

    csr

  • Reply to

    Awesome quotes from the article

    by jbkenser Aug 1, 2014 2:33 PM
    csr1223 csr1223 Aug 1, 2014 5:28 PM Flag

    Also, we could see interesting preliminary results from the stroke trial over the next year as well.

    Sentiment: Strong Buy

  • Reply to

    Awesome quotes from the article

    by jbkenser Aug 1, 2014 2:33 PM
    csr1223 csr1223 Aug 1, 2014 4:23 PM Flag

    Pro, thanks for the props.

    I've been invested here a very long time, and the news just keeps getting better and better. No other Biotech I own has the potential I see in CUR (though I will throw in a plug for CLDN with their recently received break through therapy designation from the FDA for treating heart failure- phase II fully enrolled and expected readout by next April). Still, nothing compares to the potential Neuralstem is showing. I mean, ALS, Alzheimers, stroke, spinal cord injury, depression, PTSD, et. al.

    Further, I think it could get very interesting after the first patient is treated in the spinal cord injury trial at UCSD (expected sometime this month). People can debate the results of the ALS trial even in the face of unprecedented results from the likes of Ted Harada, however, nobody will be debating the results from the spinal cord injury trial if patients start to regain meaningful use of their legs. Game over if patient(s) respond in this trial. Game, Set and Match, IMHO this could happen before the end of the year.

    Sentiment: Strong Buy

  • crains detroit

    Thursday, the last of 15 operations on ALS patients in the Phase 2a part of the human trials — involving the injection of 8 million embryonic stem cells in the cervical region and another 8 million in the lumbar region — was performed at Emory University Hospital in Atlanta.

    Feldman hopes to begin the next part of the trials, which will involve 32 ALS patients, in January or February. Meanwhile, tests will continue of the 15 patients in the Phase 2a trial to determine how the injection of the stem cells slows down the progression of the disease.

    “So far, there appears to be a prominent signal in patients showing a progression in the disease,” she said. The first of the patients was operated on last October.

    Re:Alzheimers:
    Data from the first round of injections of 50,000 stem cells into a line of mice that have inherited genes for Alzheimer’s disease.

    “Look at this data,” said Feldman, pointing to her computer screen. “I’m so geeked about this.”

    Two neurosurgeons on her team injected two groups of Alzheimer’s mice, one group with a saline solution to serve as a control, the other with the stem cells. Both those groups and a group of healthy mice were then put through three tests of cognition, including one that required finding a platform hidden in a pool of water.

    Plots of performance show that the Alzheimer’s mice injected with cells performed the tests just as well as healthy mice. The Alzheimer’s mice injected with saline solution flunked the tests.

    “We’ve never seen data like this. It’s just amazing. It’s fabulous data that we’re just getting ready to publish,” said Feldman. “They’re as normal as normal mice. They’ve essentially gone back to normal. And the effect was durable for the four months we tested them.

    “I mean, you can tell looking at the mice which ones got stem cells. The ones who got saline solution just sat there in a cage. The stem-cell mice are all running around.”

    Sentiment: Strong Buy

  • csr1223 csr1223 Jul 12, 2014 12:12 PM Flag

    In other words, I may have an opportunity to triple my investment in this hidden gem. Sounds like great news!

    Sentiment: Strong Buy

  • Reply to

    Looking at the results of the first Cupid trial

    by cash2go Jun 24, 2014 12:37 AM
    csr1223 csr1223 Jun 27, 2014 11:11 AM Flag

    dawg,

    IMHO CLDN is also undervalued due to it being a gene therapy company. If this were a traditional small molecule or Ab biological drug instead of a viral delivered gene therapy I believe the market cap would already be multiples higher based on the early trial results and the FDA Breakthru therapy designation. Looking forward to phase two results and, hopefully, early approval. Given the huge market opportunity and early investment by Big Pharma here I think positive results will likely result in a buyout. Those who wait for phase II results will miss out on the majority of the gains IMHO. Also believe Bluebird's recent results on their B-thal trial are currently helping the gene therapy space and CLDN.

    Sentiment: Strong Buy

  • Reply to

    Steven Cohen down 17 million from where he bought

    by usagary1 Jun 25, 2014 10:20 AM
    csr1223 csr1223 Jun 25, 2014 11:10 AM Flag

    Gary,

    Given the fact that Mr. Cohen is widely known for making huge $$ shorting stocks (especially Bios) I would not consider Steve Cohen owning any of my Bio stocks a good sign. He may own a lot of shares long but who knows how many shares he has sold short? I would feel much better if Mr. Cohen just slithered away from this stock altogether.

  • wwwDOTnatureDOTcom/gt/journal/vaop/ncurrent/full/gt201453aDOThtml

  • csr1223 csr1223 Jun 13, 2014 12:30 PM Flag

    Jon,

    As always, thanks for the info. If I read this correctly, it seems these Biopolymers target and deliver their payloads to tumors independent of the payload. If they are efficient enough it might be interesting to try with a morpholino targeting CD47.

    Best,

    csr

NWBO
5.84-0.03(-0.51%)Aug 29 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.